Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Privacy Policy
  • Contact US

Insight, China's Pharmaceutical Industry Fineline Info & Tech is a comprehensive global pharmaceutical database that spans the entire product lifecycle. Its mission is to equip professionals and executives across all sectors of the life sciences industry with a standardized data language, offering a holistic view of the Chinese pharmaceutical competitive landscape. Flcube.com furnishes critical data essential for informed decision-making, drawing on global industry news, policy insights, competitive intelligence, and advanced analytical tools.

Company Deals PIC

Suzhou AsiFlyer Biotechnology Secures Exclusive Worldwide License from ShanghaiTech University for AI‑Designed Recombinant Botulinum Toxin Patent

Fineline Cube Sep 8, 2026
Company Deals PIC

Liaocheng University and Shanghai Maiboxing Biotechnology Sign RMB 19 Million Pact to Co‑Develop LCUGZ1007 – Next‑Generation E‑PDC Probody Drug Conjugate

Fineline Cube Sep 8, 2026
Company Deals PIC

China Biotech’s Panboron BNCT Hospital Signs Strategic Pact with OncoCare Cancer Centre HK – Launching Cross‑Border BNCT Oncology Cooperation

Fineline Cube Sep 8, 2026
Company Deals PIC

Guangdong Taienkang Completes Capital Increase in Procapzoom – Secures Exclusive China Rights to World‑First Ocular Surface Cell Therapy SZ018

Fineline Cube Sep 8, 2026
Company Deals PIC

HepaBio Therapeutics Raises Series A Strategic Funding From TriApex to Advance Organoid Technology and Next‑Generation Drug R&D Systems

Fineline Cube Sep 7, 2026
Company Deals PIC

Suzhou AsiFlyer Biotechnology Secures Exclusive Worldwide License from ShanghaiTech University for AI‑Designed Recombinant Botulinum Toxin Patent

Fineline Cube Sep 8, 2026
Company Drug

Shionogi Wins TGA Marketing Authorization in Australia for Cefiderocol – Siderophore Cephalosporin Targeting Carbapenem‑Resistant Gram‑Negative Infections

Fineline Cube Sep 8, 2026
Policy / Regulatory

China’s CDE Releases 110th Batch of Reference Preparations for Generic Quality and Consistency Evaluation – 27 New Drugs Added in Draft Open for Public Feedback

Fineline Cube Sep 8, 2026
Company Deals

Haihe Biopharma Grants Taiho Pharmaceutical Exclusive License for Risovalisib in Japan

Fineline Cube Oct 16, 2025

China‑based Haihe Biopharma Co., Ltd. (the “Licensor”) announced today that it has entered into an...

Company Deals

Genesis Healthcare & MGI Sign Strategic MOU to Accelerate Precision Medicine in Japan

Fineline Cube Oct 16, 2025

Genesis Healthcare, a leading Japanese genetic‑testing provider, today announced the signing of a Memorandum of...

Company Deals

Nuance Pharma Partners with Stallergenes Greer to Launch Actair in China

Fineline Cube Oct 15, 2025

Nuance Pharma, an innovation-focused biopharmaceutical company, and Stallergenes Greer, a global leader in the allergy...

Policy / Regulatory

Pfizer CEO Bourla Highlights Benefits of China Biotech Collaborations at NY Gala

Fineline Cube Oct 15, 2025

Albert Bourla, CEO of Pfizer Inc. (NYSE: PFE), highlighted the benefits of collaborations between multinational...

Company Deals

Uni-Bio Science Partners with Sinovac to Expand Teriparatide Injection Globally

Fineline Cube Oct 15, 2025

Uni-Bio Science Group Limited (HKG: 0690), a China-based company, announced on September 12, 2025, that...

Company Deals

Adagene Expands Exelixis Collaboration to Include Third Target Using SAFEbody Technology

Fineline Cube Oct 15, 2025

Adagene Inc. (NASDAQ: ADAG) announced on September 16, 2025, that its collaboration and license agreement...

Company Deals

Ollin Biosciences Launches With $100M Funding to Advance Ophthalmology Pipeline

Fineline Cube Oct 15, 2025

Ollin Biosciences, Inc. (Ollin), a clinical-stage biopharmaceutical company, announced its launch on September 16, 2025,...

Company Deals

Yanyin Tech and CirCode Biomed Forge Three-Year RNA Drug Development Partnership

Fineline Cube Oct 15, 2025

Yanyin Tech and Shanghai CirCode Biomed Co. Ltd. have announced a three-year strategic cooperation agreement...

Company Deals

China Resources Double-Crane Partners with Rigerna on siRNA Drug RG008 for Chronic Metabolic Diseases

Fineline Cube Oct 15, 2025

China Resources Double-Crane Pharmaceutical Co., Ltd (SHA: 600062) and Suzhou Rigerna Therapeutics have entered into...

Company Deals

Livzon Launches China’s First Oral GnRH Antagonist for Multiple Indications

Fineline Cube Oct 15, 2025

Livzon Pharmaceutical Group Inc. (HKG: 1513), a China-based company, announced on September 10, 2025, the...

Company Deals

Pacific Shuanglin’s Controlling Stake Transferred to CNBG in RMB 4.7B Deal

Fineline Cube Oct 15, 2025

Pacific Shuanglin Bio-pharmacy Co., Ltd. (SHE: 000403), a China-based blood products company, announced that its...

Company Deals

Jingze Bio and CMS Subsidiary Partner to Commercialize Key Products in Reproduction and Ophthalmology

Fineline Cube Oct 15, 2025

On September 12, 2025, Jingze Biopharmaceutical (Hefei) Co., Ltd., based in China, and a subsidiary...

Company Deals

Yanyin Tech and ChangJiang Pharma Partner to Advance AI in Drug Development

Fineline Cube Oct 15, 2025

China-based Yanyin Tech and YiChang HEC ChangJiang Pharmaceutical Co., Ltd. announced on September 12, 2025,...

Drug

Sino Biopharmaceutical’s Partner CTTQ Secures Breakthrough Therapy Designation for TQ‑B3234 Capsule in China

Fineline Cube Oct 15, 2025

Jiangsu Chia Tai Tianqing Pharmaceutical Co., Ltd. (CTTQ), a subsidiary of China‑based Sino Biopharmaceutical Ltd. (HKG: 1177), today...

Company Drug

Pfizer Reports Positive Phase 3 HER2CLIMB‑05 Results for TUKYSA (Tucatinib) in First‑Line HER2+ MBC

Fineline Cube Oct 15, 2025

Pfizer Inc. (NYSE: PFE) today announced compelling topline results from the Phase 3 HER2CLIMB‑05 trial, evaluating...

Company Deals

Zennova & Rapafusyn Forge Alliance to Accelerate Non‑Degrading Molecular Glue Therapies

Fineline Cube Oct 15, 2025

Zennova Pharmaceutical announced today a strategic partnership with U.S.‑based biotech Rapafusyn Pharmaceuticals to jointly develop...

Company Deals Drug

Shenzhen Kangtai Secures 530 Million Yuan Technology Transfer for Klebsiella Pneumoniae Vaccine

Fineline Cube Oct 15, 2025

Shenzhen Kangtai Biological Products Co., Ltd. (SHE: 300601) today announced the signing of a technology‑transfer...

Company Drug

Eisai & Biogen Secure TGA Approval for Lecanemab (Leqembi) in Early Alzheimer’s Disease

Fineline Cube Oct 15, 2025

Japanese pharmaceutical giant Eisai Co., Ltd. (TYO: 4523) and U.S. biopharma Biogen Inc. (NASDAQ: BIIB)...

Company Deals

GenScript’s ProBio Secures RMB 479.7 M License Payment for LM‑299, Boosting SinoBiopharmaceutical’s Portfolio

Fineline Cube Oct 15, 2025

GenScript Biotech Corporation (HKG: 1548) today announced that its Contract‑Development‑and‑Manufacturing‑Organization (CDMO) platform, ProBio, received a...

Company Deals Drug

Chengdu Olymvax Biopharmaceuticals & Delonix Bioworks Announce Joint Development of Gene‑Engineered Pertussis Vaccine

Fineline Cube Oct 15, 2025

Chengdu Olymvax Biopharmaceuticals Inc. and Delonix Bioworks Co., Ltd. today announced a strategic collaboration and...

Posts pagination

1 … 145 146 147 … 718

Recent updates

  • Shionogi Wins TGA Marketing Authorization in Australia for Cefiderocol – Siderophore Cephalosporin Targeting Carbapenem‑Resistant Gram‑Negative Infections
  • China’s CDE Releases 110th Batch of Reference Preparations for Generic Quality and Consistency Evaluation – 27 New Drugs Added in Draft Open for Public Feedback
  • Shanghai Pharmaceuticals Signs Strategic Framework Pact with CAS Institute of Materia Medica to Bridge Drug Discovery and Industrial Translation
  • CanSino Biologics Signs Strategic Pact with DeepGeneAI to Co‑Develop mRNA Personalized Therapeutic Cancer Vaccines – Targeting GI and Rare Tumors Globally
  • Insilico Medicine Partners with Byterna Therapeutics to Build Next‑Generation mRNA AI‑Native R&D Engine – Targeting Circular mRNA Personalized Cancer Vaccines
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • PIC
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Shionogi Wins TGA Marketing Authorization in Australia for Cefiderocol – Siderophore Cephalosporin Targeting Carbapenem‑Resistant Gram‑Negative Infections

Policy / Regulatory

China’s CDE Releases 110th Batch of Reference Preparations for Generic Quality and Consistency Evaluation – 27 New Drugs Added in Draft Open for Public Feedback

Company Deals

Shanghai Pharmaceuticals Signs Strategic Framework Pact with CAS Institute of Materia Medica to Bridge Drug Discovery and Industrial Translation

Company Deals

CanSino Biologics Signs Strategic Pact with DeepGeneAI to Co‑Develop mRNA Personalized Therapeutic Cancer Vaccines – Targeting GI and Rare Tumors Globally

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

© 2026 Fineline Information & Technology. Independent intelligence on China's pharmaceutical industry. Not investment advice. | BlogData by Themeansar.